Literature DB >> 21931955

Structural characterization of heparins from different commercial sources.

Fuming Zhang1, Bo Yang, Mellisa Ly, Kemal Solakyildirim, Zhongping Xiao, Zhenyu Wang, Julie M Beaudet, Amanda Y Torelli, Jonathan S Dordick, Robert J Linhardt.   

Abstract

Seven commercial heparin active pharmaceutical ingredients and one commercial low molecular weight from different manufacturers were characterized with a view profiling their physicochemical properties. All heparins had similar molecular weight properties as determined by polyacrylamide gel electrophoresis (M(N), 10-11 kDa; M(W), 13-14 kDa; polydispersity (PD), 1.3-1.4) and by size exclusion chromatography (M(N), 14-16 kDa; M (W), 21-25 kDa; PD, 1.4-1.6). one-dimensional (1)H- and (13)C-nuclear magnetic resonance (NMR) evaluation of the heparin samples was performed, and peaks were fully assigned using two-dimensional NMR. The percentage of glucosamine residues with 3-O-sulfo groups and the percentage of N-sulfo groups and N-acetyl groups ranged from 5.8-7.9%, 78-82%, to 13-14%, respectively. There was substantial variability observed in the disaccharide composition, as determined by high performance liquid chromatography (HPLC)-mass spectral analysis of heparin lyase I-III digested heparins. Heparin oligosaccharide mapping was performed using HPLC following separate treatments with heparin lyase I, II, and III. These maps were useful in qualitatively and quantitatively identifying structural differences between these heparins. The binding affinities of these heparins to antithrombin III and thrombin were evaluated by using a surface plasmon resonance competitive binding assay. This study provides the physicochemical and activity characterization necessary for the appropriate design and synthesis of a generic bioengineered heparin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931955      PMCID: PMC3205190          DOI: 10.1007/s00216-011-5367-7

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  27 in total

1.  2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity.

Authors:  Robert J Linhardt
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

2.  Control of the heparosan N-deacetylation leads to an improved bioengineered heparin.

Authors:  Zhenyu Wang; Bo Yang; Zhenqing Zhang; Mellisa Ly; Majde Takieddin; Shaker Mousa; Jian Liu; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2011-04-12       Impact factor: 4.813

3.  Impact of autoclave sterilization on the activity and structure of formulated heparin.

Authors:  Julie M Beaudet; Amanda Weyers; Kemal Solakyildirim; Bo Yang; Majde Takieddin; Shaker Mousa; Fuming Zhang; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2011-03-17       Impact factor: 3.534

4.  Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin.

Authors:  Zhongping Xiao; Britney R Tappen; Mellisa Ly; Wenjing Zhao; Lauren P Canova; Huashi Guan; Robert J Linhardt
Journal:  J Med Chem       Date:  2010-12-17       Impact factor: 7.446

5.  Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis.

Authors:  Bo Yang; Amanda Weyers; Jong Youn Baik; Eric Sterner; Susan Sharfstein; Shaker A Mousa; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Anal Biochem       Date:  2011-04-15       Impact factor: 3.365

6.  Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.

Authors:  R J Linhardt; D Loganathan; A al-Hakim; H M Wang; J M Walenga; D Hoppensteadt; J Fareed
Journal:  J Med Chem       Date:  1990-06       Impact factor: 7.446

7.  Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives.

Authors:  R E Edens; A al-Hakim; J M Weiler; D G Rethwisch; J Fareed; R J Linhardt
Journal:  J Pharm Sci       Date:  1992-08       Impact factor: 3.534

8.  Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1.

Authors:  Suzanne C Edavettal; Karen A Lee; Masahiko Negishi; Robert J Linhardt; Jian Liu; Lars C Pedersen
Journal:  J Biol Chem       Date:  2004-04-01       Impact factor: 5.157

9.  Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.

Authors:  U Lindahl; G Bäckström; L Thunberg; I G Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

10.  Structure of heparin-derived tetrasaccharides.

Authors:  Z M Merchant; Y S Kim; K G Rice; R J Linhardt
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

View more
  19 in total

1.  Analysis of 3-O-sulfo group-containing heparin tetrasaccharides in heparin by liquid chromatography-mass spectrometry.

Authors:  Guoyun Li; Bo Yang; Lingyun Li; Fuming Zhang; Changhu Xue; Robert J Linhardt
Journal:  Anal Biochem       Date:  2014-03-28       Impact factor: 3.365

2.  FGF-FGFR signaling mediated through glycosaminoglycans in microtiter plate and cell-based microarray platforms.

Authors:  Eric Sterner; Luciana Meli; Seok-Joon Kwon; Jonathan S Dordick; Robert J Linhardt
Journal:  Biochemistry       Date:  2013-12-06       Impact factor: 3.162

3.  Combinatorial one-pot chemoenzymatic synthesis of heparin.

Authors:  Ujjwal Bhaskar; Guoyun Li; Li Fu; Akihiro Onishi; Mathew Suflita; Jonathan S Dordick; Robert J Linhardt
Journal:  Carbohydr Polym       Date:  2014-11-07       Impact factor: 9.381

4.  Structure and activity of a new low-molecular-weight heparin produced by enzymatic ultrafiltration.

Authors:  Li Fu; Fuming Zhang; Guoyun Li; Akihiro Onishi; Ujjwal Bhaskar; Peilong Sun; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2014-03-14       Impact factor: 3.534

Review 5.  Recent advances in biotechnology for heparin and heparan sulfate analysis.

Authors:  Meng Qiao; Lei Lin; Ke Xia; Jun Li; Xing Zhang; Robert J Linhardt
Journal:  Talanta       Date:  2020-06-14       Impact factor: 6.057

6.  A purification process for heparin and precursor polysaccharides using the pH responsive behavior of chitosan.

Authors:  Ujjwal Bhaskar; Anne M Hickey; Guoyun Li; Ruchir V Mundra; Fuming Zhang; Li Fu; Chao Cai; Zhimin Ou; Jonathan S Dordick; Robert J Linhardt
Journal:  Biotechnol Prog       Date:  2015-07-16

7.  Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus.

Authors:  Joshua J Ziarek; Christopher T Veldkamp; Fuming Zhang; Nathan J Murray; Gabriella A Kartz; Xinle Liang; Jidong Su; John E Baker; Robert J Linhardt; Brian F Volkman
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

8.  Stable isotopic analysis of porcine, bovine, and ovine heparins.

Authors:  John P Jasper; Fuming Zhang; Russell B Poe; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2014-09-03       Impact factor: 3.534

9.  Structural characterization of pharmaceutical heparins prepared from different animal tissues.

Authors:  Li Fu; Guoyun Li; Bo Yang; Akihiro Onishi; Lingyun Li; Peilong Sun; Fuming Zhang; Robert J Linhardt
Journal:  J Pharm Sci       Date:  2013-03-21       Impact factor: 3.534

10.  High cell density cultivation of a recombinant E. coli strain expressing a key enzyme in bioengineered heparin production.

Authors:  Odile Francesca Restaino; Ujjwal Bhaskar; Priscilla Paul; Lingyun Li; Mario De Rosa; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2013-01-15       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.